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Circular RNAs (circRNAs) are a class of RNAs that is under increasing scrutiny, although their functional roles are debated.
We analyzed RNA-seq data of 348 primary breast cancers and developed a method to identify circRNAs that does not rely
on unmapped reads or known splice junctions. We identified 95,843 circRNAs, of which 20,441 were found recurrently. Of
the circRNAs that match exon boundaries of the same gene, 668 showed a poor or even negative (R<0.2) correlation with
the expression level of the linear gene. In silico analysis showed only a minority (8.5%) of circRNAs could be explained by
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known splicing events. Both these observations suggest that specific regulatory processes for circRNAs exist. We confirmed
the presence of circRNAs of CNOT2, CREBBP, and RERE in an independent pool of primary breast cancers. We identified
circRNA profiles associated with subgroups of breast cancers and with biological and clinical features, such as amount
of tumor lymphocytic infiltrate and proliferation index. siRNA-mediated knockdown of circCNOT2 was shown to signifi-
cantly reduce viability of the breast cancer cell lines MCF-7 and BT-474, further underlining the biological relevance of
circRNAs. Furthermore, we found that circular, and not linear, CNOT2 levels are predictive for progression-free survival
time to aromatase inhibitor (AI) therapy in advanced breast cancer patients, and found that circCNOT2 is detectable in
cell-free RNA from plasma. We showed that circRNAs are abundantly present, show characteristics of being specifically
regulated, are associated with clinical and biological properties, and thus are relevant in breast cancer.
[Supplemental material is available for this article.]
It is a sign of the times that the ubiquitous use ofmassively parallel
sequencing data has delivered a parade of new insights in the can-
cer field and has enriched our genomic vocabulary with events
like chromothripsis, kataegis, and mutational and rearrangement
signatures (Stephens et al. 2011; Maher and Wilson 2012; Nik-
Zainal et al. 2012, 2016; Alexandrov et al. 2013). Sequencing
RNA has had less of an impact on this vocabulary, with many re-
ports concerning traditional gene expression analysis. However,
depending on the methodology of generating the sequencing li-
brary, RNA-seq has the potential to study the large variety of
RNA species, including noncoding RNAs, fusion transcripts,
known and novel isoforms, and, recently gaining attention, circu-
lar RNAs (circRNAs). This class of RNA was discovered many de-
cades ago (Hsu and Coca-Prados 1979), and circRNAs were long
considered idiosyncrasies of the splicing machinery processing
precursor mRNA into mature mRNA. More recent studies show-
ed an unanticipated abundance of circRNAs (Salzman et al.
2012; Memczak et al. 2013) in (normal and malignant) human
cells and became particularly interesting for the cancer research
field with the description (Hansen et al. 2013; Memczak et al.
2013) of a circRNA that functions as a highly potentmiR-7 sponge.
miR-7 has a well-described role in several malignancies, including
breast cancer, and functions as a tumor suppressor inmost cancers
(for review, see Zhao et al. 2015) but has also been reported
(Foekens et al. 2008) as a potential tumor promoter in breast can-
cer. Other circRNAs and additional regulatory transcriptional roles
have subsequently been described in cancer (Salzman et al. 2013;
Guo et al. 2014; Li et al. 2015b; Kristensen et al. 2018). Because
circRNAs lack a free 5′ or 3′ end, such molecules escape exonucleic
acid degrading enzymes,making themmore stable (Memczak et al.
2013) than their linear counterparts. Therefore, circRNAs repre-
sent potentially useful biomarker candidates for diagnosis and
therapy-monitoring; indeed, cell-free circRNAs are present in exo-
somes (Li et al. 2015a) and saliva (Bahn et al. 2015). In breast can-
cer, little has been described except for one study (Nair et al. 2016)
using the The Cancer Genome Atlas (TCGA) data bank. However,
this cohort has a huge limitation because the RNA-seq data were
prepared using a poly(A) selection step, thereby omitting the ma-
jority of circRNAs (as these lack a poly(A) tail).
Here we describe the identification of an extensive catalog of
circRNAs in a large cohort of 348 primary breast tumors, using
RNA-seq data obtained via random-primed cDNA synthesis
(Smid et al. 2016), likely preserving all the circRNAs.We developed
a circRNA mapping algorithm that, in contrast to previous identi-
fication methods (Salzman et al. 2012; Memczak et al. 2013; Guo
et al. 2014; Nair et al. 2016; Szabo and Salzman 2016), does not
rely on unmapped reads or on known splice junctions and that
was applied directly on transcriptome sequence BAM files, thereby
allowing the identification of circRNAs in a genome-wide and an-
notation-independent (Szabo and Salzman 2016) fashion.
Results
Identification of a plethora of circRNAs in primary breast cancer
In total, 95,843 circRNAswere identified (Fig. 1), of which 27% (n=
25,783) had a start and end position exactly matching to an exon
belonging to the same gene (Fig. 2A). The vastmajority (79%) of all
circRNAs were not recurrent (i.e., only found in one sample). The
number of circRNAs per sample (Fig. 2B) ranged from 37 to 7105
(median, 966). For recurrent circRNAs, found in at least two sam-
ples, the range per sample was 33 to 5269 (median, 834.5).
Figure 2B also shows that the number of (recurrent) circRNAs is sig-
nificantly higher in estrogen receptor (ER)-negative compared
with ER-positive breast cancers (Mann–Whitney U test, P<1 ×
10−5 for both all and recurrent circRNAs). Because of the extraordi-
nary abundance of candidate circRNAs, we focused on the—still
sizeable—number of recurrently found circRNAs (n =20,441) (total
number in second bar of Fig. 2A). The most frequent recurring re-
gion in our cohort was the well-characterized (Hansen et al. 2013;
Memczak et al. 2013; Kristensen et al. 2018) circRNA of CDR1,
which was found in 339 out of 348 cases. Other previously report-
ed and validated (Salzman et al. 2012) circRNAs such as CAMSAP1,
FBXW4,MAN1A2, RNF220, ZBTB44, andXISTwere also identified
Figure 1. Schematic overview of identifying circular RNA (circRNA) re-
gions. Assuming a circRNA molecule is present, a sequence read crossing
the junction (green arrow) and its read-mate (gold arrow) would map to
a linear reference in the manner depicted. The junction read would get
multiple alignments, and the read-mate would be located in between
the position of the junction read. Multiple read-pairs at the same junction
strengthen the support for the circRNA. Subsequent additional filtering
(details are in the Methods section) and annotation produced the list of
circRNA regions.
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in our cohort. A full list of identified circRNAs is provided in
Supplemental Table S1.
General characteristics
Recurrent circRNAs were distributed across the genome, with one
region on Chromosome 11 showing many closely spaced
circRNAs (Supplemental Fig. S1). This region contains MALAT1,
a highly abundant long noncoding RNA that is also frequently
mutated in breast cancer (Nik-Zainal et al. 2016). Next, we evaluat-
ed the intron sizes upstreamof and downstream from the circRNAs
that match exon boundaries. Confirming previously reported re-
sults (Jeck et al. 2013; Zhang et al. 2014; Ivanov et al. 2015),
Figure 2C shows that introns next to circRNA regions are signifi-
cantly larger than introns not adjacent to circRNAs: on average
2.33 and 2.27 times larger, respectively, for introns upstream of
and downstream from the circRNA (Mann–Whitney U test, both
P< 1×10−5).
Next, we correlated the number of circRNA reads per circRNA
with the expression of the respective full, linear gene, because a
previous report in a limited cell line panel reported no genome-
wide correlation between the circular and linear counterpart
(Salzman et al. 2013). To avoid spurious correlations, only those
circRNAs found in at least 50 samples were considered (n=1625),
and data were first normalized using the trimmed mean of M-val-
ues (TMM) (Robinson andOshlack 2010). Correlations are listed in
Supplemental Table S1 and ranged between −0.34 and 0.97, with
210 circRNAs showing a negative correla-
tion to the linear gene in which the
circRNA is located. When considering
the average and standard deviation of
the distribution of all correlation coeffi-
cients, 30 circRNAs are at the low end of
the distribution (P<0.05), showing a cor-
relation below R=−0.182. Finally, by us-
ing GENCODE information, the position
of annotated start codons was matched
to the circRNA positions. circRNAs recur-
ring in at least 50 samples showed an al-
most threefold higher than expected
presence of a start codon compared
with circRNAs that were not recurring
(χ2, P<0.0001; 557 circRNAs; expected
207.3 circRNAs).
Are circRNAs distinct molecules,
specifically regulated, or splicing
residues?
Many of the circRNAs that are positively
correlated with the expression level of
the full-length linear transcript are
thought to be a residue of splicing. Figure
3A shows an example; the circRNA of ex-
ons 3, 4, and 5 of theWDR1 gene (Chr 4:
10,097,711–10,103,986, with a correla-
tion coefficient of R= 0.66 to overall
gene expression) exactly matches the dif-
ference between the known linear iso-
forms of this gene (Ensembl transcript
ENST00000499869 includes exons 3, 4,
and 5; ENST00000502702 lacks these ex-
ons). As current quantificationmethods do not take circRNAs into
account, reads originating from the circular molecule are errone-
ously included in the read count of a linear isoform, resulting in
an overestimation of the overall expression level. Another compre-
hensive example of a circRNA as splicing residue is shown in Figure
3B for ESR1. Full-length ESR1 (ENST00000206249) has eight ex-
ons, whereas ENST0000 0406599 is a splice variant of ESR1 that
skips exons 2 to 5. circRNAs are found for several of these exons,
indicating that they are likely splicing residues. We speculate
that a single splice event from exons 1 to 6 generates an RNAmol-
ecule containing exons 2–5, from which a multitude of distinct
circRNAs can be derived. In total, 23 patients show both a circESR1
exon 2–3 and a circESR1 of exon 4–5. If these circRNAs are derived
from the same RNA molecule, the linear transcript would be
ENST00000406599. A sequential model, in which first exons 2
and 3 are spliced out would prohibit the formation of a circRNA
molecule of exons 3 to 4. However, we observed circESR1 exon
2–3 in 110 patients and circESR1 exon 3–4 in 64 patients, with
29 patients showing both these circRNAs. These must be derived
from separate RNA molecules.
To investigate whether or not in general circRNAs should be
considered splicing residues, we systematically evaluated how
many of the identified circRNAs exactly match those exons that
make up the difference between known linear isoforms of a
gene. By using theGENCODE annotation for each gene, every pos-
sible known combination of spliced exons was matched to our
circRNA catalog. Of the 25,783 circRNAs that matched to exons
A
B
C
Figure 2. General characteristics of circRNAs in primary breast cancer. (A) Numbers of unique and re-
current circRNAs. Purple and gold indicate the number of circRNAs that, respectively, did or did not have
a start and end position of a circRNA region exactly matching the start and end position of an exon of the
same gene. (B) The number of circRNAs per sample, grouped by ER status. In black, the total number of
circRNAs; in peach, the number of recurrent (identified in at least two samples) circRNAs. (C) Violin plots
of the intron size (in log base pair) of noncircular regions and those located directly upstream of or down-
stream from a circRNA region.
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of the same gene, only 2193 (8.5%) exactly matched exons known
to differ between described isoforms of a gene. This was 16.9% for
the circRNAs with a correlation coefficient of R>0.5 to linear gene
expression. This suggests that the vast majority of circRNAs that
matched to exons of the same gene are generated by yet-unknown
splicing events of the gene.
Because the majority of circRNAs did not match to known
spliced exons, we manually inspected several highly recurrent
circRNAs in theUCSCGenomeBrowser. For example, two isoforms
of CREBBP are described (ENST00000262367 and ENST00000
382070) that differ in the presence of exon 5 (of note, there are
10 additional known transcripts, but all of these transcripts start
downstream from exon 5). However, we observed exon 2 as
circRNA (Chr 16: 3,850,297–3,851,009) that was present in 160 pa-
tients (Fig. 3C), indicating that this circRNA is either specifically
generated or is a splicing residue of a yet-undescribed isoform of
CREBBP that skips this exon. Visual inspection of 10 samples that
had high levels of circCREBBP exon 2 (at least 30 circular junction
reads) showed two samples that each had one read that crossed
the junction from exon 1 to exon 3, whereas the other samples
showed no evidence of an isoform that skipped exon 2. This favors
the notion that the circRNAof exon 2 is not a byproduct of splicing
at this location.
Finally, we matched publicly available circRNA lists to gather
(indirect) evidence of functional roles for circRNAs. Rybak-Wolf
and colleagues reported (Rybak-Wolf et al. 2015) 4522 circRNAs
in the mammalian brain that were evolutionarily conserved be-
tween human and mouse, which is considered an indication of
function (Barbosa-Morais et al. 2012;Merkin et al. 2012). Of these,
2259 circRNAs (49.9%) were also present in our catalog. In addi-
tion, 3271 circRNAs were reported in an MCF-7 breast cancer
cell line panel (Tarrero et al. 2018). In to-
tal, 922 circRNAs showed (increased) ex-
pression in estrogen-stimulated MCF-7
cells compared with cells cultured in hor-
mone-deprived medium, of which 733
circRNAs (79.5%) were present in our
list. A poor correlation (R<0.2) with the
linear transcript was observed in our data
for 78 of these circRNAs, suggesting inde-
pendent regulation fromtheir linear gene
instead of ER-induced overall higher ex-
pression of all transcripts from that gene.
Validation of circRNAs
Besides the fact that we detected sever-
al already published circRNAs, thereby
in part validating our method, we per-
formed RT-PCR on a previously estab-
lished independent cDNA pool of 100
primary breast tumors to confirm expres-
sion of three circRNAs, namely, RERE
(circRNA Chr 1: 8,541,214–8,614,686),
CNOT2 (circRNA Chr 12: 70,278,132–
70,311,017), and CREBBP (circRNA Chr
16: 3,850,297–3,851,009), all of which
were poorly correlated with their linear
counterpart. Figure 4 shows the PCR frag-
ment sizes; expected and observed sizes
were 89 and 155 bp for the small and big-
ger CNOT2 fragment, 100 bp for RERE,
and 91 bp for CREBBP. The primer pair for CNOT2was able to am-
plify the circRNA of exon 2 to exon 3 of CNOT2 but also the
circRNA of exons 2, 3, and 4 of this gene (a circRNA that was
also identified in the RNA-seq cohort).
A different primer pair to PCR circCNOT2 showed additional
fragments in addition to the expected fragments of 140 and 206
bp (Supplemental Fig. S2A). Sanger sequence analysis confirmed
the circular junction sequence from exon 3 to exon 2 of CNOT2
(Supplemental Fig. S2B) and from exon 4 to exon 2 (Supplemental
Fig. S2C). After using BLAST to identify the sequence, the largest
excised PCR fragment was found to contain an additional exon
of CNOT2 (Chr 12: 70,294,237–70,294,293) located between
exon 2 and exon 3 that is not present in most isoforms of
CNOT2 (Supplemental Fig. S2D). The sequence showed exon 3,
across the circular junction to exon 2, but reading through the lo-
cationwhere the reverse primer was located, continuing thewhole
of exon 2, the additional exon, and ending in exon 3 again
B
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Figure 3. circRNAs are not just residues of splicing. (A) Sashimi plot of the number of reads that are
aligned toWDR1, showing only the reads that span exons. In red are the normal exon–exon reads; in pur-
ple, the reads that span the circular junction. The line and boxes indicate the exons of the gene (thewhole
gene is not shown). (B) Isoform of ESR1. The arcs indicate the number of samples that have a particular
circRNA. (C) Two isoforms of CREBBP that are known in the first five exons (other isoforms are described,
but these start downstream from exon 5). Exon 2 (purple box) is an identified circRNA that is not a re-
mainder of a splicing event.
Figure 4. PCR products of circRNAs. PCR product sizes of circRNAs visu-
alized using the MultiNA Microchip Electrophoresis System. (M) DNA size
marker (25-bp fragment ladder); (−) the negative control (genomic DNA).
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(Supplemental Fig. S2D). A likely explanation for this observation
is that during cDNAgeneration, the RT polymerase generated a lin-
ear cDNAmolecule containingmultiple copies of the circular tran-
script (Supplemental Fig. S2E). In summary, the investigated
circRNAs were all confirmed to be truly present in primary breast
cancer.
Functional relevance of circRNAs in breast cancer cells
The potential functional relevance of the validated circCNOT2 and
circCREBBP transcripts, which were both poorly correlated with
their corresponding linear transcript, was evaluated in breast can-
cer cell lines. First, expression levels of circCNOT2 and circCREBBP
were established in a panel of 55 cell lines, showing variable levels
(Supplemental Fig. S3). Next, an siRNAwas designed to specifically
target the circular junction of circCNOT2 in bothMCF-7 (moderate
expression level) and BT-474 (high expression level). This siRNA
reduced expression of circCNOT2 by 76% in MCF-7 and 71% in
BT-474 breast cancer cells, relative to cells transfected with a non-
targeting control (NTC), which resulted in significantly reduced vi-
ability of bothMCF-7 and BT-474 cells (Student’s t-test, P<1×10−5
and P=4.94×10−4, respectively) (Fig. 5).
circRNAs in driver genes
We matched our previously reported breast cancer driver gene list
(Nik-Zainal et al. 2016) to our circRNA list. In total, 235 recurrent
circRNAs were identified in 54 breast cancer driver genes. To inte-
grate the data and obtain sufficient observations for analysis, we
selected samples for which we had both RNA and genomic DNA
sequencing results available and selected the genes with somati-
cally acquired genetic events (mutations, copy number variants,
and rearrangements) in at least 10 patients, yielding a list of 10
genes; TP53, PIK3CA, PTEN, MAP3K1, CDH1, RB1, MAP2K4,
ARID1B, ARID1A, and MLLT4. For genes with multiple circRNAs,
the circular region with the highest recurrence was chosen for
analysis, with the exception of TP53, for which we only found
two circRNAs in just one sample each (see Table 1). Only for
MAP2K4 was mutual exclusivity observed between the presence
of a somaticmutation or a circRNA in this cohort, inwhich20 sam-
ples had a somatic mutation, 77 samples had a circRNA (Chr 17:
12,054,889–12,113,360), and only two samples had both a muta-
tion and a circRNA (P=0.025, CoMEt exact test) (Leiserson et al.
2015). For PIK3CA, 25 patients showed a DNA event and a
circRNA, three patients with a copy number aberration (amplifica-
tion), and 22 patients with a base substitution in PIK3CA. These
substitutions were located in four hotspots, p.H1047 (13 cases),
p.E545 (n=4), p.E542 (n=3), and p.E726 (n=2). None of these hot-
spots was located in the circRNA region that was found in these
samples.
Breast cancer relevance
To investigate common biology in the samples, we used multiple
correspondence analysis (MCA) to find naturally occurring sub-
groups. MCA is a generalized principle component analysis, suit-
able for categorical data. We used recurrent circRNAs (at least
50 cases) with the junction annotated to exons of the same gene
(n= 1625) and labeled these per sample as circular or not circular,
based on the presence or absence of junction reads in a sample.
Themainpatient groupswere, not unexpectedly, dividedbyER sta-
tus (Fig. 6A, left), whereas within circRNAs, the main division was
whether or not the gene had a circRNA (Fig. 6A, right). Additional
variation within the circRNAs was explained by the level of recur-
rence of the circRNAs (see Supplemental Fig. S4). Next, the pres-
ence/absence of circRNAs in a sample was used to cluster all
samples into groups with distinct circRNA profiles. We used the
gap statistic (Tibshirani et al. 2001) to determine the optimal num-
ber of sample groups, yielding six clusters (Fig. 6B; Supplemental
Fig. S5).We evaluated these six sample groups on ER and tumor in-
filtrating lymphocyte (TIL) status (Fig. 6C,D), number of circRNAs
(Fig. 6E), and outcome for the patients in the clusters (Fig. 6F).
Samples in cluster 1 and3were predominantly ER-negative,where-
as ER positivity was predominantly present in groups 2, 4, 5, and
6. TIL status was established using a previously reported gene ex-
pression signature (Massink et al. 2015; Smid et al. 2016), labeling
samples as high-TIL if the average expression of the TIL signature
genes fell into the top quartile (n=87, 45 ER-negative and 42 ER-
positive) (Fig. 6D, respectively, labeled as red and orange). High-
TIL cases were significantly (χ2 P<1×10−5) more often present in
clusters 1 (71% of cases) and 3 (45% of cases). Furthermore, the
number of circRNAs per sample clearly distinguished the six clus-
ters (Fig. 6E), showing a decreasing number of circRNAs from clus-
ters 1 to 6. Finally, for a subset of 186 patients, relapse-free survival
Figure 5. siRNA-mediated knockdown of circCNOT2 affects viability in
breast cancer cells. The effect of reduced circCNOT2 expression on viability
is shown in MCF-7 and BT-474 cells. Both cell lines show a significant
decrease in viability (P<0.01) following circCNOT2 knockdown relative
to cells transfected with nontargeting control (NTC). Error bars, SD of
five wells.
Table 1. Number of samples with a DNA event and/or circRNA
circRNA region
Gene
symbol
No. of samples
DNA
events circRNA Both
Chr 17: 7,673,535–7,674,290 TP53 105 1 0
Chr 17: 7,674,859–7,676,622 TP53 105 1 1
Chr 3: 179,203,544–179,204,588 PIK3CA 84 77 25
Chr 10: 87,925,513–87,952,259 PTEN 47 13 4
Chr 5: 56,864,734–56,865,977 MAP3K1 30 210 22
Chr 16: 68,801,670–68,815,759 CDH1 22 7 0
Chr 13: 48,342,599–48,349,023 RB1 22 4 0
Chr 17: 12,054,889–12,113,360 MAP2K4 20 77 2
Chr 6: 156,829,227–156,935,576 ARID1B 14 28 1
Chr 1: 26,729,651–26,732,792 ARID1A 12 213 11
Chr 6: 167,870,383–167,889,326 MLLT4 10 28 0
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data were available; a survival plot for the
six clusters (Fig. 6F) showed that the ma-
jor difference was between clusters 1 and
3,which are bothpredominantly ER-neg-
ative. Although thenumberof eventswas
low, direct comparison of cluster 1 with
cluster 3 showed a significant difference
in survival curves (log rank, P=0.04).
Differentially expressed circRNAs
We investigated if circRNA expression
levels were associated with clinically rele-
vant features of primary breast cancer,
such as presence of TILs, the tumor’s stro-
mal content, proliferation, and hypoxia
status. These features were inferred from
generated (stroma; see Methods) or re-
ported (Winter et al. 2007; Massink
et al. 2015; Smid et al. 2016) gene ex-
pression signatures. By using these, we
grouped our samples in a similar manner
as explained earlier for the TIL status (Fig.
6D), labeling samples as high if the aver-
age expression of the signature genes fell
into the top quartile. To identify signifi-
cantly differentially expressed circRNAs,
we compared the top quartile of samples
to the remaining samples separately
for the ER-positive and ER-negative
cases. circRNAs with FDR-corrected
P-values <0.05 and a fold-change greater
than two were selected. Of these, the
circRNAs that had a negative correlation
with the linear gene expressionwere con-
sidered of particular interest and are list-
ed in Table 2. Several of these circRNAs
may thus potentially play a role in, or
are at least connected to, the tumors
that show hypoxic characteristics (e.g.,
circKMT2C) or accumulate in highly pro-
liferative cells (e.g., circRERE, circATXN2),
whereas, for example, circASH1L and
circPCH3may be generated by surround-
ing stromal cells or infiltrating cells.
Clinical relevance
One of the reasons CNOT2 was selected
for validation was because of the poor
correlation with expression of the linear
gene (R=−0.09, P=0.34). This was more
prominent in ER-positive (R=−0.14)
compared with ER-negative cases (R=
0.097).Wevalidated this finding bymak-
ing use of in-house array data (Smid et al.
2008) for linear CNOT2 expression and
a quantitative RT-PCR assay to measure
circCNOT2 (exon 2–3 Chr 12: 70,278,
132–70,311,017). The Spearman’s corre-
lation in ER-positive cases of circCNOT2
with linear CNOT2 was 0.079 (n =
187, P=0.28) and in ER-negative cases
E F
B
A
C
D
Figure 6. Analysis of sample groups according to circRNA presence. Multiple correspondence analysis
(MCA) was used to find naturally occurring groups in the circRNA data. In an MCA plot, samples and
circRNAs are projected onto the same plane, in which the relative distance to either the samples or
the circRNAs is meaningful. The 0,0 point corresponds to a sample or circRNA with an average profile.
(A, left) Samples are colored according to ER status: red, ER-positive; black, ER-negative. (Right) Purple
and green indicate genes with or without circRNA expression, respectively. (B) Clustering identified sam-
ples with similar circRNA profiles; samples in the MCA plot are colored according to the cluster to which
the sample belongs. (C) ER status (purple, ER-positive; peach, ER-negative) and (D) TIL status of the six
sample groups: Red and orange are high-TIL cases and blue and green are low-TIL cases for ER-negative
and ER-positive, respectively. (E) Number of circRNAs per sample group. (F) Relapse-free survival plot by
sample group. (N) number of patients; (F) number of patients who relapse; (x-axis) months; (y-axis) the
cumulative probability of relapse-free survival.
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Rs=0.42 (n=111, P=2.9 ×10−6), again showing absence of correla-
tion in ER-positive cases. Thus, the role of circCNOT2 apparently
differs between ER-positive and ER-negative cases, and in the
ER-negative cases, the significance of circCNOT2 cannot be easily
segregated from the linear counterpart. Therefore, we evaluated
two different ER-positive breast cancer cohorts (Supplemental
Table S3 shows clinical characteristics) for thepotential clinical val-
ue of circCNOT2.We studied progression-free survival of aromatase
inhibitor (AI) therapy in a multicenter cohort of 84 ER-positive
patients who received this treatment for advanced disease.
Quantitative reverse transcriptase–PCR (RT-qPCR) levels of
circCNOT2 showeda significanthazard ratio (HR)of 1.75 (95%con-
fidence interval1.32–2.33,P=1.06×10−4),whereasRT-qPCRlevels
of linearCNOT2were not significant: HR 1.28, P=0.187. Figure 7A
shows a survival curve after grouping patients’ circCNOT2-levels
into three equally sized groups. A similar analysis in another cohort
(Sieuwerts et al. 2005), which included patients receiving first-line
tamoxifen treatment (n=295 patients), did not show a significant
HR (0.97, P=0.57) for circCNOT2 or for
linear CNOT2 (HR 1.16, P=0.21).
As circularmolecules are expected to
be more stable than their linear counter-
parts, we explored whether circCNOT2 is
a potential candidate as minimally in-
vasive biomarker. To this end, we used
cell-free RNA (cfRNA) from plasma sam-
ples of four breast cancer patients and
amplified circCNOT2 by RT-qPCR. All
samples showed detectable and variable
levels of circCNOT2 (Fig. 7B), indicating
that detection of circRNAs in plasma
seems attainable in this exploratory
setting.
Discussion
To our knowledge, we are the first to an-
alyze RNA sequencing data using ran-
dom-primed cDNA libraries from a large
primary breast cancer cohort for the presence of circRNAs, using
a method that does not rely on unmapped reads. Previously,
Nair and colleagues (Nair et al. 2016) analyzed TCGA RNA-seq
data that were obtained using a poly(A)-based method. Although
we identified 25,783 circRNAs that matched with an exon boun-
dary of the same gene, Nair et al. (2016) reported 2146 circRNAs
when we applied the same selection criteria as for our data set,
and after transferring the hg37 coordinates (Nair et al. 2016) to
hg38 (our data set), only 45 circRNAs were found that had the ex-
act same start and end coordinates in both data sets. Thus, a ran-
dom-primed method identifies many more circRNAs than when
using poly(A)-selected material. On the other hand, there seem
to be many uniquely identified circRNAs in these data sets. This
could stem fromdifferences in themethodology to detect or report
the circRNAs but also could reflect the fact that many circRNAs are
nonrecurrent.
We showed that circRNAs are found throughout the genome
and have significantly larger-sized introns located directly
Table 2. Fold-change of circRNAs in top quartile of samples versus remaining samples in ER-subgroups of tumors
Regions
Gene
symbol
Hypoxia Proliferation Stroma TIL
ER-
negative
ER-
positive
ER-
negative
ER-
positive
ER-
negative
ER-
positive
ER-
negative
Chr 1: 155,438,327–155,459,898 ASH1L 2.0 2.1 2.0
Chr 1: 8,541,214–8,557,523 RERE 2.4 2.1
Chr 1: 8,655,973–8,656,441 RERE 2.0
Chr 2: 112,399,632–112,400,194 RGPD8 2.5 2.3 2.6
Chr 3: 170,136,419–170,149,244 PHC3 3.4 2.1 2.6 2.8 2.5
Chr 5: 140,440,119–140,449,305 ANKHD1 2.2 2.2
Chr 7: 152,309,966–152,315,338 KMT2C 2.1
Chr 7: 1556,72,867–155,680,908 RBM33 2.4 2.4 2.6 2.5 2.3
Chr 7: 17,868,407–17,875,790 SNX13 2.4 2.3
Chr 10: 32,543,300–32,584,304 CCDC7 2.2 2.4
Chr 12: 111,554,158–111,555,919 ATXN2 2
Chr 13: 75,560,753–75,569,507 UCHL3 2.0
Chr 15: 25,405,461–25,411,971 UBE3A 2.7 2.2 2.4 2.1
Chr 15: 92,996,957–92,998,621 CHD2 2.4 2.3
Chr 18: 76,849,526–76,851,939 ZNF236 2.1 2.0
Chr 20: 35,716,740–35,725,155 RBM39 2.5 2.2
No significant circRNAs were identified in the TIL ER-positive group.
BA
Figure 7. Clinical evaluation and presence in plasma samples. (A) Kaplan–Meier survival curve of pro-
gression-free survival for AI therapy in which patients were grouped in three equally sized groups based
on their circCNOT2 expression: red, blue, and green indicate the samples with high, intermediate, and
low expression. The x-axis is in months; y-axis depicts the cumulative probability of progression-free sur-
vival on AI therapy. The P-value is the log-rank test for trend. (B) Expression levels of circCNOT2 in plasma
samples. Four metastatic breast cancer patients were evaluated. The y-axis depicts delta-Ct values of
circCNOT2 relative to GUSB. Error bars, SD of two measurements.
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adjacent to the region on the genome that borders the circRNA, as
also reported previously (Jeck et al. 2013; Zhang et al. 2014; Ivanov
et al. 2015). Based on the presence/absence of circRNAs, six groups
of samples were observed that differed in their ER status, TIL con-
tent, number of circRNAs, and prognosis. This indicates that there
appears to be a functional biology associatedwith the biogenesis of
circRNA molecules or at least a biology that cancerous cells can
use to their advantage. Whether or not the circRNAs themselves
serve that function orwhether the process that generates differenc-
es in circRNA levels is the cause for the results presented here
remains unknown at this time. The fact that several circRNAs
were found differentially expressed in breast cancer subgroups,
although these circRNAs are negatively correlated with the expres-
sion of the linear gene from which the circRNA is derived, corrob-
orates the notion of functional circRNAs. Further experimentation
is required to investigate the functional relationship of the differ-
entially expressed circRNAs in the hypoxia, proliferation, stroma,
and TIL phenotypes.
Although a synthetic circRNA construct including an internal
ribosome entry site (IRES) can be translated (Wang and Wang
2015), current literature (Jeck et al. 2013; Guo et al. 2014; Szabo
and Salzman 2016; Liang et al. 2017; Liu et al. 2018; Wang et al.
2018; Zeng et al. 2018) describes mostly noncoding functions for
circRNAs, for example, as miRNA sponge circCDR1 (Hansen et al.
2013; Memczak et al. 2013; Zhao et al. 2015; Kristensen et al.
2018) and circZNF91 (Guo et al. 2014), whereas associative evi-
dence was reported (Rybak-Wolf et al. 2015) of evolutionarily con-
served circRNAs between human and mouse. Further support that
circRNAs may be specifically generated and regulated was derived
from a study using (estrogen-stimulated)MCF-7 cells (Tarrero et al.
2018), showing higher levels of H3K36me3 (posttranscriptional
histone modification) and a higher number of Ago binding sites
in circularizing exons.
Here, we contribute to the search for relevant circRNAs in
three ways; first, expression levels of circRNAs that are not, or
even negatively, correlated with the linear transcript of the gene
may point to an intentional process. Although differences in deg-
radation rates between the circular and linear isoforms may influ-
ence the correlation, we did not find systemic evidence for this
(Supplemental Fig. S6). Furthermore, for genes that generate sever-
al distinct circRNAs, correlations can vary, indicating that degrada-
tion of the linear transcript cannot be the only explanation for the
observed correlations. Second, circRNAs that include the start co-
don could potentially influence the expression of the linear
gene, because the linear transcript from which the circRNA was
spliced is now forced to use another start codon for its translation;
if none is available, the transcript may be degraded. For example,
circCNOT2 (exon 2–3 Chr 12: 70,278,132–70,311,017) contains
the start codon of the consensus (Pruitt et al. 2009) transcript
(CCDS31857.1). Annotation shows that exon 1 is untranslated
and both exon 2 and exon 4 start with the methionine codon
(ATG). Thus, the linear transcript wherein exon 1 is ligated to
exon 4 lacks the start codon from exon 2 and may use the ATG
in exon 4 for its translation. Third, we observed that circRNAs
matching exon boundaries of the same gene rarely (8.5%) overlap
with known spliced exons. It could be that our analysis overlooked
possible splice variants from the GENCODE annotation (both
HAVANA and Ensembl exon annotations were included), but if
the concordance is indeed this low, two scenarios may be applica-
ble: Either circRNAs are stillmostly a remnant of splicing, implying
that many more transcript isoforms of genes exist, or otherwise
circRNAs are specifically generated, implying that they do have a
biological role. The observations of variable expression levels of
circCNOT2 and circCREBBP in cell lines and especially the effect
of circCNOT2 knockdown on cell viability corroborate a biological
role for circRNAs. Future studies are needed to systematically eval-
uate if the correlation between a circRNA and its linear transcript,
the presence of a start codon, and/or known splice junctions are
reliable criteria to prioritize circRNAs of interest.
Regardless, we were able to show clinical potential for
circCNOT2 by showing its association with the response to AI ther-
apy. Knowing that circularmolecules are not targeted by exonucle-
ases, these molecules may be suitable candidates to be detected in
cell-free environments (Li et al. 2015a), and in a pilot experiment,
we showed that circCNOT2 can indeed be detected in cfRNA from
plasma samples of breast cancer patients. As such, circCNOT2
could prove to be a useful biomarker to choose the right type of
therapy or to monitor disease in a minimally invasive manner.
Furthermore, weobserved that very likely because of the stranddis-
placement activity of the reverse transcriptase during cDNA gener-
ation, multiple concatemeric copies of a single circular molecule
are made, contributing to the sensitive detection of circRNAs. In
conclusion, we have demonstrated the abundance and potential
roles of circRNAs in primary breast cancer. The methodology and
selection criteria we used may help in making more sense of the
seeming chaos and disorder existing in the flow from DNA to
RNA to protein. circRNAs show the potential to function as rele-
vant actors in the transcriptional regulation of RNA in addition
to their promise as stable biomarkers that can be used for disease
progression.
Methods
Sequencing
Internal review boards of each participating institution approved
collection and use of samples of all patients in this study. RNA-
seq data were generated by our consortium (Nik-Zainal et al.
2016; Smid et al. 2016) for 348 primary breast cancer tumors
that are available through the European Genome-phenome
Archive under accession number EGAS00001001178. Sequence
protocols of the samples were previously described in detail (Nik-
Zainal et al. 2016); in short, total RNA after gDNA removal,
clean-up, and depletion of ribosomal RNA using duplex-specific
nuclease (DSN) treatment was used as input for random-primed
cDNA synthesis. Paired-end (75 bases) sequencing was performed
on an Illumina HiSeq 2000. The resulting FASTQ files were
mapped to GRCh38 using STAR (version 2.4.2a) (Dobin et al.
2013), and the resulting BAM files were sorted and indexed using
Sambamba (version 0.6.6) (Tarasov et al. 2015; https://github
.com/lomereiter/sambamba/). Gene annotation was derived
from GENCODE Release 23 (https://www.gencodegenes.org/).
Identification of circRNAs
A detailed explanation of the methodology to identify circRNA
reads, including the Perl script, is stated in the Supplemental
Methods. The script is also available at https://bitbucket.org/
snippets/MSmid/Le949d/identify-circularrna-reads. In short, the
method developed here uses sequence reads that have a “second-
ary alignment” (SA) tag. When using paired-end sequence data
and assuming a circRNA molecule is present (Fig. 1, top), the se-
quence read that aligns over the crossing of the junction (green
arrows) would “point toward” its read-mate (orange arrow) some-
where in the circle. Aligning these reads to the linear reference
(Fig. 1, middle), the junction read will get an SA tag and will
Circular RNAs in breast cancer
Genome Research 363
www.genome.org
 Cold Spring Harbor Laboratory Press on January 2, 2020 - Published by genome.cshlp.orgDownloaded from 
be assigned to two locations if and only if this is the one and
unique alignment configuration the STAR software can find.
The read-mate aligns somewhere in between these two locations.
Finding additional read-pairs showing this configuration, with a
breakpoint at the exact same location, strengthens the evidence
for circular transcripts. Only regions with at least five reads cross-
ing the circular junction were included. After filtering (for de-
tails, see Supplemental Methods), GENCODE annotation was
used to obtain the exon locations of genes that exactly matched
to the circular region. For each sample, STAR also gives the raw
read counts for all genes. These were normalized (TMM imple-
mented in edgeR) (Robinson and Oshlack 2010) and used to
correlate with the number of junction reads of the circular
transcripts.
Multiple correspondence analysis
Because many genes only show a linear transcript in many sam-
ples, standard cluster analysis to identify groups of samples with
similar circRNA-related biology is problematic because of the
many missing values. Thus, the circRNA data were considered cat-
egorical using “circular” or “not circular” if a circRNA was present
or absent in a sample. These categorical data are suitable for an
MCA, a generalization of a principle component analysis. The
MCA generates a combined plot that shows both patients and
circRNAs such that patients/circRNAs that have similar patterns
are closer together. R-packages “ade4,” “canceracm,” and “cluster”
were used to perform the MCA and determine the optimum num-
ber of clusters. The latter was determined using the clusGap option
(k-means to partition the samples) in the cluster package. R version
3.4.1 was used (R Core Team 2017).
Reverse transcription, PCR, and Sanger sequencing
Candidate circRNAs were selected and primers were designed such
that a PCR would only yield a product when the RNAwas circular,
whereas in the linear situation, the primers would be divergent.
Primer sequences are listed in Supplemental Table S2.
First, total RNA, isolated with RNA-Bee according to the
manufacturer’s instructions (CS105B, TEL TEST) was reverse tran-
scribed into cDNA with the RevertAid H Minus first-strand cDNA
synthesis kit (K1632; Thermo Fisher Scientific), followed by a
RNase H step (AM2293; Ambion). Next, circRNAs were real-
time PCR amplified at 10 ng input in a final volume of 25 µL us-
ing 40 PCR cycles and an annealing temperature of 67°C with
330 nM of each primer and SensiFAST SYBR Lo-ROX mastermix
(BIO-94050, Bioline), followed by a final 5-min extension at
72°C, in a MX3000P (Agilent Technologies). PCR products were
visualized using a MultiNA microchip electrophoresis system
(Shimadzu).
For sequencing, PCR fragments were separated on a standard
agarose gel and were excised from gel using the QIAquick gel
extraction kit from Qiagen according to manufacturer’s protocol.
The sequencing reaction contained 2 µL of gel-extracted PCR pro-
duct, 1 µL BigDye terminator v3.1 reaction mix (Thermo Fisher
Scientific), 1× BigDye terminator sequencing buffer (Thermo
Fisher Scientific), and 0.16 µM of sequencing primer in a final vol-
ume of 10 µL and was performed using an ABI2720 thermal cycler
according to the following protocol: one step for 2min at 96°C and
25 cycles of 30 sec at 96°C , 30 sec at 58°C, and 2 min at 72°C.
Subsequently, the sequencing product was precipitated with abso-
lute ethanol and 3M of NaAc, resuspended in 20 µL of Hi-Di form-
amide (Thermo Fisher Scientific), and ran on an ABI3130XL
genetic analyzer (Thermo Fisher Scientific).
RT-qPCR
After RNA isolation and cDNA synthesis performed as described
above, circCNOT2 (Chr 12: 70,278,132–70,311,018) and
circCREBBP (Chr 16: 3,850,297–3,851,009) transcripts were real-
time PCR amplified at 10 ng input in a final volume of 25 µL in
40 PCR cycles and an annealing temperature of 60°C with 200
nM of each primer and 100 nM Fam-labeled TaqMan MGB probe
that covers the circular junction (Thermo Fisher Scientific)
(Supplemental Table S2) in SensiFAST Probe Lo-ROX mastermix
(BIO-84020, Bioline) using a MX3000P (Agilent Technologies).
Levelswerequantified relative to theaverageexpressionof three ref-
erence genes (HPRT1,HMBS, and TBP) (Supplemental Table S2) us-
ing thedeltaCqmethod (dCq=2(average Cq reference genes–Cq target gene))
(Schmittgen and Livak 2008). A serially diluted cDNA pool
(Sieuwerts et al. 2014) of 100 independent breast tumor samples
(containing both ER-positive/-negative and ERBB2-positive cases)
was included in each experiment to evaluate the linear amplifi-
cation and efficiencies for all genes and absence of amplification
in the absence of reverse transcriptase. Samples in the cDNA pool
were independent from the cases that were used for the RNA-seq
cohort.
Detection of circRNAs in plasma
cfRNA was isolated with the Maxwell RSC miRNA tissue kit
(Promega) adapted for plasma according the manufacturer’s in-
structions. One milliliter of EDTA plasma of different metastatic
breast cancer patients was used. These patients provided written
informed consent. Six microliters of the resulting 50 µL cfRNA
(3.8–7 ng RNA/µL) was used to generate 20 µL cDNA with the
SuperScript IV VILO cDNA synthesis kit (Thermo Fisher
Scientific). Next, 2 µL of the cDNA was preamplified in the pres-
ence of 0.50 nM of the reverse primers of the hydrolysis probe as-
says for circCNOT2 andGUSB as a referencemarker during 15 cycles
with TaqMan preamp mastermix (Thermo Fisher Scientific).
Finally, 0.5 µL of the preamplified product was measured real-
time with the hydrolysis probe assays (200 nM forward primer,
200 nM reverse primer, and 100 nM FAM-labeled hydrolysis
MGB probe) during 40 cycles with SensiFAST Probe Lo-ROX mas-
termix (BioLine) in a final qPCR volume of 25 µL in a MX3000P
qPCR machine (Agilent Technologies).
siRNA-mediated knockdown of circRNAs and cell
viability assay
All cell lines in this study were established to be genetically unique
and monoclonal and of correct identity by performing STR profil-
ing using the PowerPlex 16 system (Promega). MCF-7 and BT-474
were plated at 60%–70% confluency in six-well plates and trans-
fected with 50 nM ON-TARGETplus siRNA targeting circCNOT2
(Horizon Discovery) using 4 µL (MCF-7) or 8 µL (BT-474)
DharmaFECT 1 (Horizon Discovery) following the manufacturer’s
instructions. Used sequences (5′-3′) were as follows: sense, AAA
GAUAGGGAGACGUGGUUU; antisense, 5′-PACCACGUCUCCC
UAUCUUUUU. The ON-TARGETplus nontargeting pool and On-
TARGETplus human UBB smart pool were included in each exper-
iment as negative and positive controls, respectively (Horizon
Discovery). After 24hof transfection, cellswere trypsinized, count-
ed, and seeded in quintuplicate at 20,000 cells per well in 96-well
plates.Cell viabilitywasdeterminedusing theCellTiter-Blue cell vi-
ability assay (Promega) at day 0 and day 3. Viabilitymeasurements
at day 3 were corrected for baseline viability values by subtracting
the average measurement of day 0.
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Gene expression signatures
Weused several signatures: a TIL and proliferation signature (Smid
et al. 2016), a hypoxia signature (Winter et al. 2007), and a stroma-
specific signature using public data GSE5847 (Gene Expression
Omnibus) (Boersma et al. 2008). We performed a paired t-test to
obtain genes significantly higher expressed in microdissected
stroma (FDR<0.05 and fold-change >1.7). For all signatures, genes
that were up-regulated in the category of interest were matched to
our data set, and the average expression of the signature genes was
calculated per sample. Sampleswere labeled as high-TIL (or stroma,
proliferation, hypoxia) if the average expression of the signature
genes fell into the top quartile. To identify significantly dif-
ferentially expressed circRNAs, we compared the top quartile of
samples versus the rest, per ER-group. circRNAswere only included
when detected in >50% of the samples and matched known
exon locations of the same gene. Analyses were performed using
BRB-ArrayTools developed by Dr. Richard Simon and the BRB-
ArrayTools development team. circRNAs were considered signifi-
cant when the FDR corrected P-value was below 0.05 and the
fold-change greater than 2.
Breast cancer cohort treated with endocrine therapy
RT-qPCRwas performed on a linear and circular isoform ofCNOT2
(Chr 12: 70,278,132–70,311,017) in a first-line TAM (Sieuwerts
et al. 2005) and a first-line AI cohort to study the predictive value
of circCNOT2 on therapy response. The AI cohort was a multicen-
ter cohort consisting of 30 patients from Erasmus MC, Rotterdam;
35 patients from The Netherlands Cancer Institute, Amsterdam;
and 19 patients from the Translational Cancer Research Unit,
Antwerp (Belgium). All 295 patients in the TAMcohort are patients
of the Erasmus MC, Rotterdam. Patient characteristics are listed in
Supplemental Table S3.
Statistical analyses
STATA version 14 was used to perform the statistical tests that are
indicated in the text. P-values are two-sided, corrected for multiple
testing when necessary, and considered significant below 0.05.
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